晶泰控股(02228.HK)已收到与DoveTree订立的最终协议项下约定的5100万美元的首付款

Core Insights - JingTai Holdings (02228.HK) announced a final agreement with DoveTree Medicines LLC and its affiliates to utilize its AI+robotics-based end-to-end drug discovery platform for developing small molecules and antibody candidates targeting oncology, immunology, inflammation, neurological disorders, and metabolic disorders [1] Group 1 - The agreement involves JingTai's subsidiary, Shenzhen JingTai Technology Co., Ltd., which will collaborate with DoveTree on drug discovery [1] - DoveTree will receive exclusive global development and commercialization rights for the identified products [1]